TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35377878
Drug: Integrated mass
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated mass drug administration (MDA) for STH and mass dog rabies vaccination (MDRV)
Study: 36328878
Drug: Exercise program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise program (twice a week for twelve weeks, 60 min sessions including warm-up, progressive resistance training, and cool-down)
Study: 36328878
Drug: Exercise program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise program (twice a week for twelve weeks)
Study: 32816521
Drug: Walking boot
Normalized name: Booty Goo
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Walking boot treatment
Study: 32814997
Drug: Ixekizumab 80
Normalized name: ixekizumab 80 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab 80 mg every 2 weeks (Q2W)
Study: 32814997
Drug: Ixekizumab 80
Normalized name: ixekizumab 80 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab 80 mg every 4 weeks (Q4W)
Study: 36372613
Drug: Anthocyanins (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthocyanins (320 mg/d for 24 weeks)
Study: 35962334
Drug: Multi-session Cognitive
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-session Cognitive Behavioural Therapy (CBT)
Study: 32729897
Drug: Ranibizumab 0.5
Normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.5 mg every 4 weeks
Study: 32729897
Drug: Faricimab 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faricimab 6.0 mg every 12 weeks
Study: 32729897
Drug: Faricimab 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faricimab 6.0 mg every 16 weeks
Study: 32729897
Drug: Faricimab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faricimab (both dosing schedules)
Study: 36420523
Drug: Maqui berry-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maqui berry-based nutraceutical (MBN) supplementation, 1,000 mg/day for 30 days
Study: 34857236
Drug: L. reuteri
Normalized name: L. reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. reuteri DSM 17938
Study: 32406284
Drug: Herbal creams
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal creams (Centella asiatica, Cucumis sativus, Thunbergia laurifolia) and commercial moisturizing cream
Study: 32406284
Drug: Cucumis sativus
Normalized name: CUCUMIS SATIVUS LEAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cucumis sativus cream
Study: 32962673
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) injection into the wound at 4 and 12 postoperative days
Study: 32127657
Drug: Plerixafor +
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plerixafor + standard mobilization (G‐CSF ± chemotherapy)
Study: 36096929
Drug: Age, BMI,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age, BMI, hypertension, dyslipidemia, total fat area (TFA), visceral fat area (VFA), visceral‐to‐subcutaneous fat ratio (VSR), waist circumference (WC)
Study: 32014311
Drug: Test group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test group with individualized protamine titration based on ACT measurements
Study: 32014311
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with standard protamine infusion of 1.3 mg per 1 mg (100 U) of heparin
Study: 34464242
Drug: Budesonide/formoterol (Bud
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol (Bud + Form; 400/12 µg BID)
Study: 34464242
Drug: Fluticasone/salmeterol (Flu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone/salmeterol (Flu + Salm; 250/50 µg BID)
Study: 34464242
Drug: Formoterol only
Normalized name: Formoterol only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol only (Form; 12 µg BID)
Study: 36179772
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonists (VKAs) among adherent patients
Study: 36179772
Drug: Direct oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct oral anticoagulants (DOACs) among adherent patients
Study: 33851966
Drug: NP202, 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: NP202, 1000 mg, daily for 3 months
Study: 35064715
Drug: Community-based multi-month
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based multi-month dispensing (MMD) of antiretroviral treatment (ART) with options for 3-monthly or 6-monthly dispensing.
Study: 33957389
Drug: Vinpocetine 10
Normalized name: vinpocetine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinpocetine 10 mg oral
Study: 33957389
Drug: Vinpocetine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinpocetine 20 mg oral
Study: 33957389
Drug: Vinpocetine 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinpocetine 60 mg oral
Study: 33957389
Drug: Vinpocetine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinpocetine 20 mg oral three times a day (one-month open label)
Study: 32403130
Drug: 12-week intensive
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week intensive intervention comprising lifestyle approaches and treatment with insulin glargine, metformin, and dapagliflozin
Study: 33663316
Drug: Dapoxetine taste-masked
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapoxetine taste-masked oral thin films (OTFs) with pullulan, glycerol, AmberLite, and dapoxetine (30 mg)
Study: 36381457
Drug: Half-saline (HS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-saline (HS) irrigation solution
Study: 36381457
Drug: Normal-saline (NS)
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-saline (NS) irrigation solution
Study: 33257672
Drug: SOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOX regimen (3 cycles of tegafur gimeracil oteracil potassium capsule plus oxaliplatin)
Study: 36469329
Drug: Housing remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Housing remediation or trash cleanup treatment
Study: 33961292
Drug: Low-dose cytosine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cytosine arabinoside (LDAC) plus tosedostat (LDAC-T)
Study: 33961292
Drug: Low-dose cytosine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cytosine arabinoside (LDAC)
Study: 33996039
Drug: Interviewer-administered seven-day
Normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interviewer-administered seven-day semi-quantitative food frequency questionnaire (7-d SQFFQ)
Study: 32321570
Drug: Extended-release naltrexone
Normalized name: bupropion / naltrexone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release naltrexone (XR-NTX) before release
Study: 32321570
Drug: Enhanced XR-NTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced XR-NTX (mobile medical treatment post-release)
Study: 32321570
Drug: XR-NTX (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: XR-NTX (standard referral to community treatment program post-release)
Study: 32507439
Drug: Garlic powder
Normalized name: Garlic Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic powder supplementation (400 mg per tablet, 4 tablets daily for 12 weeks)
Study: 32507439
Drug: Placebo (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (400 mg starch per tablet, 4 tablets daily for 12 weeks)
Study: 34323454
Drug: Sphenopalatine ganglion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sphenopalatine ganglion block (SPGB) in treatment group A
Study: 34737187
Drug: Liraglutide (1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (1.8 mg daily for 5 weeks after 2 weeks of titration)
Study: 34016825
Drug: Centrifuged adipose
Normalized name: human adipose preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centrifuged adipose tissue injection
Study: 34016825
Drug: No injection
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No injection of centrifuged adipose tissue (control)
Study: 32404059
Drug: Community-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based intervention (up to three in-home visits, monthly group wellness program, monthly case conferencing, care coordination)
Study: 34559090
Drug: Memantine 10
Normalized name: Memantine 10mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine 10 mg daily for 10 days, then 20 mg daily for 21 days
Study: 34559090
Drug: Placebo (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (same shape and size as memantine tablets)
Study: 32491932
Drug: Cabozantinib in
Normalized name: Product containing cabozantinib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib in combination with atezolizumab
Study: 36251140
Drug: Naoxintong Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naoxintong Capsule (1.2 g orally, twice a day)
Study: 33420602
Drug: Valerian extract
Normalized name: valerian extract
DrugBank: Valerian (DB13196)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valerian extract (530 mg for 30 nights)
Study: 33420602
Drug: Placebo (530
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (530 mg for 30 nights)
Study: 32845475
Drug: Endobronchial coils
Normalized name: BOIL-EASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endobronchial coils treatment
Study: 34326642
Drug: Fluoxetine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine + CBT
Study: 34326642
Drug: Fluoxetine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine + Bupropion
Study: 34326642
Drug: Fluoxetine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine + Bupropion + Brain Stimulation
Study: 33954859
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of orthokeratology and 0.01% atropine (OKA group)
Study: 32756204
Drug: Nasal high-flow
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high-flow (NHF) therapy with room air only and no supplemental oxygen
Study: 32756204
Drug: Face mask
Normalized name: CVS Face Masks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face mask oxygen administration
Study: 33788453
Drug: Sufentanil patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil patient-controlled intravenous analgesia plus sham EA (without stimulation)
Study: 35358455
Drug: Anetumab ravtansine
Normalized name: Anetumab ravtansine
DrugBank: Anetumab ravtansine (DB14809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anetumab ravtansine (6.5 mg/kg on day 1 of each 21-day cycle)
Study: 35358455
Drug: Vinorelbine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine (30 mg/m2 once every week)
Study: 33637926
Drug: Scale and
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scale and Polish (S&P) 6-monthly
Study: 33637926
Drug: Scale and
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scale and Polish (S&P) 12-monthly
Study: 33637926
Drug: Usual Oral
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual Oral Hygiene Advice (OHA)
Study: 36103212
Drug: High dosing
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dosing grape seed flour (GSF ≈ 1 g/kg)
Study: 35904063
Drug: Oral carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral carvedilol 5 mg bid (twice per day)
Study: 34297363
Drug: Prebiotic inulin‐type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic inulin‐type fructans (ITF) 16 g/d
Study: 34297363
Drug: Control supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control supplement (maltodextrin) 16 g/d
Study: 38295317
Drug: Chemotherapy only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy only (CT)
Study: 34558200
Drug: Milvexian (4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milvexian (4, 20, 60, 200, 300, or 500 mg)
Study: 34558200
Drug: Milvexian (once-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milvexian (once- or twice-daily for 14 days)
Study: 34558200
Drug: Milvexian (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milvexian (various doses)
Study: 34558200
Drug: Milvexian (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milvexian (200 and 500 mg)
Study: 34728476
Drug: Inhaled ciclesonide
Normalized name: ciclesonide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled ciclesonide (600 μg twice daily) and intranasal ciclesonide (200 μg daily)
Study: 34728476
Drug: Placebo (metered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (metered dose inhaler and nasal saline)
Study: 36116516
Drug: Ultra-low-dose quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low-dose quadruple combination therapy
Study: 33331916
Drug: Once-weekly oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly oral azithromycin for 48 weeks
Study: 32171328
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) - Structured Material for Therapy (SMART), 6-week intervention
Study: 32171328
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) - SMART
Study: 35650629
Drug: Immediate online
Normalized name: FILTER,SUCTION,INLINE #FHBF200S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate online assessment and subsequent sector-independent treatment coordination (ASSIST)
Study: 32608096
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard community treatment)
Study: 35803894
Drug: Internet-based psychodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based psychodynamic therapy (IPDT)
Study: 34048587
Drug: Lower serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower serum ferritin levels (<100 ng/mL)
Study: 34048587
Drug: Ferritin levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferritin levels above 194 ng/mL
Study: 32617701
Drug: American ginseng
Normalized name: American ginseng
DrugBank: Panax quinquefolius whole (DB14296)
Approvals — FDA: no, EMA: no, PMDA: no
Description: American ginseng 1000 mg per day for 8 weeks
Study: 33534516
Drug: Weekly empathic
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly empathic communication email reminders
Study: 33403940
Drug: 2000 mg
Normalized name: bran 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg of extended-release niacin orally once daily for 24 weeks
Study: 35301911
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MCE and HIFE
Study: 32341641
Drug: Nebulized glycopyrrolate
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized glycopyrrolate (GLY) 25 µg twice daily
Study: 32696585
Drug: Cobimetinib (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cobimetinib (10 mg single oral dose)
Study: 32186238
Drug: Suction suspension
Normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suction suspension
Study: 34193262
Drug: Combined Lactobacillus
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Lactobacillus reuteri and ω‐3 fatty acid treatment (double-treatment)
Study: 34193262
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri (single treatment)
Study: 34193262
Drug: ω‐3 fatty
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω‐3 fatty acid (single treatment)
Study: 35704085
Drug: B‐vitamin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: B‐vitamin supplementation (400 µg folic acid and 500 µg vitamin B12 daily for 2 years)
Study: 33900319
Drug: Modified alcohol-free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified alcohol-free beer (16.5 g isomaltulose and 5.28 g resistant maltodextrin per day)
Study: 33390191
Drug: Digital intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital intervention to increase adherence to nebuliser treatments, details on dosage and duration not specified.
Study: 32037213
Drug: Oral fluid
Normalized name: cascara sagrada ORAL FLUID EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluid management group (OFG)
Study: 35615299
Drug: Short course
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short course antibiotics (7 days)
Study: 35615299
Drug: Conventional course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional course antibiotics (14 days)
Study: 33721922
Drug: Low-cost and
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-cost and culturally acceptable treatment focusing on quality-of-life issues.
Study: 33721922
Drug: Integrative model
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrative model of treatment incorporating traditional practices and community support.
Study: 35027013
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (AFO/adapted shoes) for 12 weeks
Study: 33764803
Drug: Angiotensin Converting
Normalized name: Angiotensin converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin Converting Enzyme (ACE) inhibitors
Study: 33764803
Drug: Angiotensin‐2 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin‐2 receptor blockers (ARBs)
Study: 32500675
Drug: PCSA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCSA with morphine
Study: 32404130
Drug: Daily one-way
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily one-way text message intervention for 6 months
Study: 34119811
Drug: Hypnosis (used
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypnosis (used in one or several sessions, alone or as an adjunct, reinforced with daily self-hypnosis with or without audio tapes)
Study: 35605188
Drug: Lorlatinib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorlatinib (100 mg once daily)
Study: 35605188
Drug: Crizotinib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crizotinib (250 mg twice a day)
Study: 33098995
Drug: Paclitaxel (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (80 mg/m2 weekly) plus Olaparib (100 mg twice daily for 12 weeks)
Study: 33098995
Drug: Paclitaxel plus
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel plus Carboplatinum (AUC 2 weekly for 12 weeks)
Study: 33855585
Drug: Baseline IL-6
Normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline IL-6 cut-off value of 8.58 pg/mL
Study: 33855585
Drug: Baseline IL-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline IL-8 cut-off value of 57.9 pg/mL
Study: 33408308
Drug: Docetaxel/Nedaplatin (60/80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel/Nedaplatin (60/80 mg/m2/day)
Study: 33408308
Drug: Docetaxel (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (70 mg/m2/day)
Study: 32621073
Drug: Cabergoline (dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (dopamine D2 agonist)
Study: 32692751
Drug: Protein-calorie food
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-calorie food supplement offered daily to pregnant and lactating women (2.09 MJ energy and 20-25 g protein) and their offspring (1.25 MJ energy and 8-10 g protein) until the age of six years.
Study: 34265255
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection then progressive exercise
Study: 34265255
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection then best practice advice
Study: 32268257
Drug: Augmented biofeedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented biofeedback training alongside traditional physical therapy
Study: 32268257
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of augmented biofeedback training and traditional physical therapy
Study: 34485754
Drug: Calcium chloride
Normalized name: Calcium Chloride
DrugBank: Calcium chloride (DB01164)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium chloride (15 mg/kg) administered intravenously as a bolus at the beginning of weaning from CPB
Study: 34485754
Drug: 0.9% sodium
Normalized name: LMD with 0.9% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride administered intravenously as a bolus at the beginning of weaning from CPB
Study: 33616190
Drug: treatment-as-usual control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment-as-usual control group
Study: 34479732
Drug: Contrast agent
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast agent applied to the posterior ulnar recurrent artery
Study: 34479732
Drug: Contrast agent
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast agent applied to the inferior ulnar collateral artery
Study: 34479732
Drug: Contrast agent
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast agent applied to the superior ulnar collateral artery
Study: 35863991
Drug: Bevacizumab (BEV)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (BEV) during second-line chemotherapy